For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior t ...

Insulin efsitora is a new basal insulin that can be given once weekly. New research findings comparing efsitora with degludec are summarized in a short video.

Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp ...

Novo Nordisk to slash US prices of Tresiba and Fiasp insulins by over 70% from 2026, enhancing diabetes access. The company ...

3 The US FDA approved insulin glargine in 2000, followed by insulin glargine U-300 (300 units/mL) in 2005 and insulin determir and insulin degludec in 2015. 9-12 Overall, long-acting insulins are ...

while insulin glargine and insulin degludec have side effects that mean some patients are unable to take them. Novo Nordisk has been selling Levemir in the US for nearly 20 years, and in March ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes ...

Purpose. The efficacy and safety of and key clinical considerations for using U-500 insulin human regular in the treatment of high-dose insulin-treated patients in a wide variety of settings are ...